Skip to main content
SpringerLink
Log in

Management and Treatment of Contact Urticaria Syndrome

  • Chapter
  • First Online:
Contact Urticaria Syndrome

Part of the book series: Updates in Clinical Dermatology ((UCD))

  • 399 Accesses

Abstract

Contact urticaria syndrome (CUS) is characterized by the development of itchy wheals and/or eczematous dermatitis that usually appears within minutes after the contact with an eliciting substance. Over the years, advances in the knowledge of the pathogenesis of this condition have caused changes in its classification, diagnosis, and treatment. Management of CUS is similar to that of other diseases caused by hypersensitivity reactions. Thus, the safest and most effective measure is the complete avoidance of the particular allergen. In cases where prevention has failed and symptoms interfere too greatly with the patient’s career and/or quality of life, pharmacological agents could be used to provide symptomatic relief. Nevertheless, this pharmacological therapy could vary depending on the type of immediate contact skin reaction and its pathophysiology. Herein, we discuss the different therapeutic options available for the management of CUS and review the mechanisms by which these agents might achieve their therapeutic effects on patients with CUS.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wakelin SH. Contact urticaria. Clin Exp Dermatol. 2001;26(2):132–6.

    Article  CAS  PubMed  Google Scholar 

  2. Gimenez-Arnau A, Maurer M, De La Cuadra J, Maibach H. Immediate contact skin reactions, an update of contact urticaria, contact urticaria syndrome and protein contact dermatitis – “A never ending story”. Eur J Dermatol. 2010;20(5):552–62.

    PubMed  Google Scholar 

  3. Maibach HI, Johnson HL. Contact urticaria syndrome. Contact urticaria to diethyltoluamide (immediate-type hypersensitivity). Arch Dermatol. 1975;111(6):726–30.

    Article  CAS  PubMed  Google Scholar 

  4. Aquino M, Mawhirt S, Fonacier L. Review of contact urticaria syndrome- evaluation to treatment. Curr Treat Options Allergy. 2015;2(4):365–80.

    Article  Google Scholar 

  5. Bhatia R, Alikhan A, Maibach HI. Contact urticaria: present scenario. Indian J Dermatol. 2009;54(3):264–8.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Wang CY, Maibach HI. Immunologic contact urticaria- the human touch. Cutan Ocul Toxicol. 2013;32(2):154–60.

    Article  CAS  PubMed  Google Scholar 

  7. Von Krogh G, Maibach HI. The contact urticaria syndrome- an updated review. J Am Acad Dermatol. 1981;5(3):328–42.

    Article  Google Scholar 

  8. McFadden J. Immunologic contact urticaria. Immunol Allergy Clin N Am. 2014;34(1):157–67.

    Article  Google Scholar 

  9. Verhulst L, Goossens A. Cosmetic components causing contact urticaria: a review and update. Contact Dermatitis. 2016;75(6):333–44.

    Article  CAS  PubMed  Google Scholar 

  10. Nicholson PJ, Llewellyn D, English JS, Guidelines Development Group. Evidence-based guidelines for the prevention, identification and management of occupational contact dermatitis and urticaria. Contact Dermatitis. 2010;63(4):177–86.

    Article  PubMed  Google Scholar 

  11. Adisesh A, Robinson E, Nicholson PJ, Sen D, Wilkinson M, Standards of Care Working Group. U.K. standards of care for occupational contact dermatitis and occupational contact urticaria. Br J Dermatol. 2013;168(6):1167–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Chowdhury MMU. Occupational contact urticaria: a diagnosis not to be missed. Br J Dermatol. 2015;173(6):1364–5.

    Article  CAS  PubMed  Google Scholar 

  13. Amaro C, Goossens A. Immunological occupational contact urticaria and contact dermatitis from proteins: a review. Contact Dermatitis. 2008;58(2):67–75.

    Article  PubMed  Google Scholar 

  14. Dean AM, Secrest AM, Powell DL. Contact urticaria from occupational exposure to formaldehyde. Dermatitis. 2016;27(4):232.

    Article  PubMed  Google Scholar 

  15. Saluja SS, Davis CL, Chong TA, Powell DL. Contact urticaria to nickel: a series of 11 patients who were prick test positive and patch test negative to nickel sulfate 2.5% and 5.0%. Dermatitis. 2016;27(5):282–7.

    Article  CAS  PubMed  Google Scholar 

  16. Gomułka K, Panaszek B. Contact urticaria syndrome caused by haptens. Postepy Dermatol Alergol. 2014;31(2):108–12.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Venarske D, deShazo RD. Molecular mechanisms of allergic disease. South Med J. 2003;96(11):1049–54.

    Article  PubMed  Google Scholar 

  18. Lahti A, Oikarinen A, Viinikka L, Ylikorkala O, Hannuksela M. Prostaglandins in contact urticaria induced by benzoic acid. Acta Derm Venereol. 1983;63(5):425–7.

    PubMed  CAS  Google Scholar 

  19. Lahti A, Väänänen A, Kokkonen EL, Hannuksela M. Acetylsalicylic acid inhibits non-immunologic contact urticaria. Contact Dermatitis. 1987;16(3):133–5.

    Article  CAS  PubMed  Google Scholar 

  20. Johansson J, Lahti A. Topical non-steroidal anti-inflammatory drugs inhibit non-immunologic immediate contact reactions. Contact Dermatitis. 1988;19(3):161–5.

    Article  CAS  PubMed  Google Scholar 

  21. Morrow JD, Minton TA, Awad JA, Roberts LJ. Release of markedly increased quantities of prostaglandin D2 from the skin in vivo in humans following the application of sorbic acid. Arch Dermatol. 1994;130(11):1408–12.

    Article  CAS  PubMed  Google Scholar 

  22. Levin C, Warshaw E. Protein contact dermatitis: allergens, pathogenesis, and management. Dermatitis. 2008;19(5):241–51.

    PubMed  Google Scholar 

  23. Kanerva L, Estlander T. Immediate and delayed skin allergy from cow dander. Am J Contact Dermat. 1997;8(3):167–9.

    PubMed  CAS  Google Scholar 

  24. Conde-Salazar L, González MA, Guimaraens D. Type I and Type IV sensitization to Anisakis simplex in 2 patients with hand eczema. Contact Dermatitis. 2002;46(6):361.

    Article  CAS  PubMed  Google Scholar 

  25. Mercader P, de la Cuadra-Oyanguren J, Rodríguez-Serna M, Pitarch-Bort G, Fortea-Baixauli JM. Treatment of protein contact dermatitis with topical tacrolimus. Acta Derm Venereol. 2005;85(6):555–6.

    PubMed  CAS  Google Scholar 

  26. Giménez-Arnau A. Contact urticaria and the environment. Rev Env Health. 2014;29(3):207–15.

    Article  CAS  Google Scholar 

  27. Alfonso JH, Bauer A, Bensefa-Colas L, Boman A, Bubas M, Constandt L, et al. Minimum standards on prevention, diagnosis and treatment of occupational and work-related skin diseases in Europe - position paper of the COST Action StanDerm (TD 1206). J Eur Acad Dermatol Venereol. 2017;31(Suppl 4):31–43.

    Article  CAS  PubMed  Google Scholar 

  28. Mälkönen T, Jolanki R, Alanko K, Luukkonen R, Aalto-Korte K, Lauerma A, et al. A 6-month follow-up study of 1048 patients diagnosed with an occupational skin disease. Contact Dermatitis. 2009;61(5):261–8.

    Article  PubMed  Google Scholar 

  29. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868–87.

    Article  CAS  PubMed  Google Scholar 

  30. Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CE, Lawlor F, et al. The definition, diagnostic testing and management of chronic inducible urticarias – The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71(6):780–802.

    Article  CAS  PubMed  Google Scholar 

  31. Deza G, Giménez-Arnau AM. Itch in urticaria management. Curr Probl Dermatol. 2016;50:77–85.

    Article  PubMed  Google Scholar 

  32. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32(4):489–98.

    Article  CAS  PubMed  Google Scholar 

  33. Jáuregui I, Ferrer M, Montoro J, Dávila I, Bartra J, del Cuvillo A, et al. Antihistamines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol. 2007;17(2):41–52.

    PubMed  Google Scholar 

  34. Khalaf AT, Li W, Jinquan T. Current advances in the management of urticaria. Arch Immunol Ther Exp. 2008;56(2):103–14.

    Article  CAS  Google Scholar 

  35. Simons FE. Advances in H1-antihistamines. N Engl J Med. 2004;351(21):2203–17.

    Article  CAS  PubMed  Google Scholar 

  36. Thurmond RL, Kazerouni K, Chaplan SR, Greenspan AJ. Antihistamines and itch. Handb Exp Pharmacol. 2015;226:257–90.

    Article  CAS  PubMed  Google Scholar 

  37. Lee EE, Maibach HI. Treatment of urticaria. An evidence-based evaluation of antihistamines. Am J Clin Dermatol. 2001;2(1):27–32.

    Article  CAS  PubMed  Google Scholar 

  38. Diepgen TL, Andersen KE, Chosidow O, Coenraads PJ, Elsner P, English J, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1–22.

    Article  PubMed  Google Scholar 

  39. Kaplan AP. Treatment of chronic urticaria: approaches other than antihistamines. In: Kaplan A, Greaves M, editors. Urticaria and angioedema. New York: Informa Healthcare; 2009. p. 365–72.

    Google Scholar 

  40. Lebwohl MG, Del Rosso JQ, Abramovits W, Berman B, Cohen DE, Guttman E, et al. Pathways to managing atopic dermatitis: consensus from the experts. J Clin Aesthetic Dermatol. 2013;6(Suppl 7):S2–18.

    Google Scholar 

  41. Kozel MMA, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs. 2004;64(22):2515–36.

    Article  CAS  PubMed  Google Scholar 

  42. Rombold S, Lobisch K, Katzer K, Grazziotin TC, Ring J, Eberlein B. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed. 2008;24(1):19–23.

    Article  CAS  PubMed  Google Scholar 

  43. Hannuksela M, Kokkonen EL. Ultraviolet light therapy in chronic urticaria. Acta Derm Venereol. 1985;65(5):449–50.

    PubMed  CAS  Google Scholar 

  44. Maxwell DL, Atkinson BA, Spur BW, Lessof MH, Lee TH. Skin responses to intradermal histamine and leukotrienes C4, D4, and E4 in patients with chronic idiopathic urticaria and in normal subjects. J Allergy Clin Immunol. 1990;86(5):759–65.

    Article  CAS  PubMed  Google Scholar 

  45. Sanada S, Tanaka T, Kameyoshi Y, Hide M. The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria. Arch Dermatol Res. 2005;297(3):134–8.

    Article  CAS  PubMed  Google Scholar 

  46. Altman K, Chang C. Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema. Clin Rev Allergy Immunol. 2013;45(1):47–62.

    Article  CAS  PubMed  Google Scholar 

  47. Marsland AM, Soundararajan S, Joseph K, Kaplan AP. Effects of calcineurin inhibitors on an in vitro assay for chronic urticaria. Clin Exp Allergy. 2005;35(5):554–9.

    Article  CAS  PubMed  Google Scholar 

  48. Wright JD, Chu HM, Huang CH, Ma C, Chang TW, Lim C. Structural and physical basis for anti-IgE therapy. Sci Rep. 2015;5:11581.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. McCormack PL. Omalizumab: a review of its use in patients with chronic spontaneous urticaria. Drugs. 2014;74(14):1693–9.

    Article  CAS  PubMed  Google Scholar 

  50. Aubin F, Avenel-Audran M, Jeanmougin M, Adamski H, Peyron JL, Marguery MC, et al. Omalizumab in patients with severe and refractory solar urticaria: a phase II multicentric study. J Am Acad Dermatol. 2016;74(3):574–5.

    Article  CAS  PubMed  Google Scholar 

  51. Metz M, Schütz A, Weller K, Gorczyza M, Zimmer S, Staubach P, et al. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017;140:864. https://doi.org/10.1016/j.jaci.2017.01.043.

    Article  PubMed  CAS  Google Scholar 

  52. Maurer M, Schütz A, Weller K, Schoepke N, Peveling-Oberhag A, Staubach P, et al. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017;140:870. https://doi.org/10.1016/j.jaci.2017.01.042.

    Article  PubMed  CAS  Google Scholar 

  53. Cirla AM. Asthma and baker’s allergy: experience with health programs. G Ital Med Lav Ergon. 2011;33(1):20–5.

    PubMed  CAS  Google Scholar 

  54. Nettis E, Di Leo E, Calogiuri G, Milani M, Delle Donne P, Ferrannini A, et al. The safety of a novel sublingual rush induction phase for latex desensitization. Curr Med Res Opin. 2010;26(8):1855–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital del Mar - Institut Mar d’Investigacions Mediques, Universitat Autònoma de Barcelona (UAB), Department of Dermatology, Barcelona, Spain

    Gustavo Deza & Ana M. Giménez-Arnau

Authors
  1. Gustavo Deza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana M. Giménez-Arnau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ana M. Giménez-Arnau .

Editor information

Editors and Affiliations

  1. Hospital del Mar - Institut Mar d’Investigacions Mediques, Universitat Autònoma de Barcelona (UAB), Department of Dermatology, Barcelona, Spain

    Ana M. Giménez-Arnau

  2. Department of Dermatology, University of California San Francisco, San Francisco, California, USA

    Howard I. Maibach

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Deza, G., Giménez-Arnau, A.M. (2018). Management and Treatment of Contact Urticaria Syndrome. In: Giménez-Arnau, A., Maibach, H. (eds) Contact Urticaria Syndrome. Updates in Clinical Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-89764-6_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-89764-6_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-89763-9

  • Online ISBN: 978-3-319-89764-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation